Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide

Androgen deprivation therapy (ADT) is an important component of systemic therapy in advanced prostate cancer; however, resistance to ADT is inevitable. Three large studies demonstrated the efficacy of novel androgen receptor (AR)-targeted therapies in prolonging metastasis-free survival and time to...

Descripción completa

Detalles Bibliográficos
Autores principales: Gul, Anita, Garcia, Jorge A, Barata, Pedro C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682169/
https://www.ncbi.nlm.nih.gov/pubmed/31534371
http://dx.doi.org/10.2147/CMAR.S165706
_version_ 1783441847462395904
author Gul, Anita
Garcia, Jorge A
Barata, Pedro C
author_facet Gul, Anita
Garcia, Jorge A
Barata, Pedro C
author_sort Gul, Anita
collection PubMed
description Androgen deprivation therapy (ADT) is an important component of systemic therapy in advanced prostate cancer; however, resistance to ADT is inevitable. Three large studies demonstrated the efficacy of novel androgen receptor (AR)-targeted therapies in prolonging metastasis-free survival and time to symptomatic progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Enzalutamide and apalutamide have been approved by the FDA in the nmCRPC setting. This review discusses the role of AR and ADT in prostate cancer, mechanism of ADT resistance and the nmCRPC stage. In addition, pharmacologic characteristics and clinical development of apalutamide, role of apalutamide in nmCRPC, and ongoing clinical studies of apalutamide in different stages of prostate cancer are discussed.
format Online
Article
Text
id pubmed-6682169
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-66821692019-09-18 Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide Gul, Anita Garcia, Jorge A Barata, Pedro C Cancer Manag Res Review Androgen deprivation therapy (ADT) is an important component of systemic therapy in advanced prostate cancer; however, resistance to ADT is inevitable. Three large studies demonstrated the efficacy of novel androgen receptor (AR)-targeted therapies in prolonging metastasis-free survival and time to symptomatic progression in patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Enzalutamide and apalutamide have been approved by the FDA in the nmCRPC setting. This review discusses the role of AR and ADT in prostate cancer, mechanism of ADT resistance and the nmCRPC stage. In addition, pharmacologic characteristics and clinical development of apalutamide, role of apalutamide in nmCRPC, and ongoing clinical studies of apalutamide in different stages of prostate cancer are discussed. Dove 2019-08-01 /pmc/articles/PMC6682169/ /pubmed/31534371 http://dx.doi.org/10.2147/CMAR.S165706 Text en © 2019 Gul et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Gul, Anita
Garcia, Jorge A
Barata, Pedro C
Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
title Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
title_full Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
title_fullStr Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
title_full_unstemmed Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
title_short Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
title_sort treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6682169/
https://www.ncbi.nlm.nih.gov/pubmed/31534371
http://dx.doi.org/10.2147/CMAR.S165706
work_keys_str_mv AT gulanita treatmentofnonmetastaticcastrationresistantprostatecancerfocusonapalutamide
AT garciajorgea treatmentofnonmetastaticcastrationresistantprostatecancerfocusonapalutamide
AT baratapedroc treatmentofnonmetastaticcastrationresistantprostatecancerfocusonapalutamide

Ejemplares similares